Sort   by:  
 Page size 
GenomicsPevonedistat sensitizes cancer cells to oncolytic VSVd51 virotherapy
Pevonedistat sensitizes cancer cells to oncolytic VSVd51 virotherapy
PRJNA850784 | ENA
GenomicsExpression profiling of CLL derived T Cells treated with pevonedistat
Expression profiling of CLL derived T Cells treated with pevonedistat
PRJNA576383 | ENA
GenomicsPevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
PRJNA766651 | ENA
TranscriptomicsPevonedistat sensitizes cancer cells to oncolytic VSVd51 virotherapy
To investigate the ability for pevonedistat to sensitize renal 786-0 carcinoma cells to VSVd51 oncolyic virotherapy, we treated cells with monotherapies or combination and sequencinced the transcriptome for antiviral interferon impact
ORGANISM(S): Homo sapiens 
2023-09-28 | GSE206428 | GEO
TranscriptomicsPevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
Targeted inhibitors of JAK2 (e.g. ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways ma...
ORGANISM(S): Homo sapiens 
2021-12-01 | GSE184850 | GEO
ProteomicsPevonedistat inhibits aberrant protein NEDDylation in Polycystic Liver Diseases.
Background: Polycystic liver diseases (PLD) are genetic disorders characterized by progressive growth of numerous liver cysts, causing significant morbidity. Previous studies revealed genes affecting protein biogenesis and more recently, protein SUMOylation, a posttranslational modification (PTM), h...
ORGANISM(S): Homo sapiens (Human) 
2022-02-16 | PXD022571 | Pride
Hepatic cystogenesis  mln4924  pevonedistat  neddylation  therapy  nae1. 
UnknownThe NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis.
Not available
S-EPMC4979425 | biostudies-literature
UnknownEffect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Not available
S-EPMC6595297 | biostudies-literature
UnknownTargeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Not available
S-EPMC5296256 | biostudies-literature
UnknownPevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.
Not available
S-EPMC5400571 | biostudies-literature
Sort   by:  
 Page size